How Leveraging Patient Insurance in SOC can Create Enrollment Barriers for your Trail and Strategies to Overcome Them

In the realm of clinical trials, patient recruitment poses a significant challenge, with merely 2%-5% of U.S. patients currently engaged in these crucial research endeavors. Patients represent the cornerstone of any clinical trial, without whom progress in developing novel therapies and advancing care innovation would stall. Consequently, ensuring patient participation and completion stands as a primary focus for clinical trial sponsors. While extensive research has been dedicated to understanding barriers to participation, such as access and indirect expenses like travel and lodging, another critical factor hindering participation and exacerbating patient drop-out emerges: the coverage of care for baseline or comparator drugs in the U.S., which contrasts with other countries like the U.K. where sponsors typically bear such costs. This disparity in coverage may disproportionately impact socio-economically vulnerable and diverse patient populations, potentially impeding their access to and engagement in vital clinical trials.

Dive into the whitepaper today to explore:

• The current state of care coverage in cancer trials
• Developing a framework to understand sponsor coverage impact
• Cost of noncoverage versus cost of coverage
• A case for coverage